Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEA-targeted CAR-T in advanced colorectal cancer with peritoneal metastases
NCT07247396Phase 1Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Nov 2025
- Primary completion
- May 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of C-13-60 in colorectal cancer (CRC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Safety of CAR-T cell preparations at 3 months and Recommended dose of CAR-T cells at 3 months. Started Nov 2025; status: recruiting.
02
Drugs
C-13-60
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07247396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07247396.